Stem Cell Therapy An Alternative To Surgery
Stem cell therapy is a revolutionary regenerative procedure that uses your own mesenchymal stem cells from your fat cells (adipose cells) or from your bone marrow to help repair the damaged or degenerative cells in your joints and encourages healing. These procedures use state-of-the-art techniques that are very ethical and safe. All of our procedures follow the FDA guidelines for MINIMAL MANIPULATION (WE DONT ADD ANY ENZYMES OR CHANGE YOUR CELLS IN ANY WAY).
Mesenchymal stem cells from your fat OR bone marrow are also called adult stem cells, and they help facilitate the regeneration of tissue naturally in the joint. These stem cells are considered to be raw potential or multipotent meaning they have the potential to differentiate into the tissue cells needed in a specific area. These cells normally function alongside the immune system and work to replace skin and tissue when the body experiences trauma. Stem Cell Therapy takes that natural regenerative ability and focuses it on the region where your body needs help repairing itself. Mesenchymal stem cells direct cytokines and growth factors from your immune system to the targeted area to create an ongoing healing process as your body repairs itself organically. Research has shown that stem cells have the potential to repair damaged cartilage, bone, tendons, muscle, skin, and connective cell tissue.
The stem cells being used are from YOUR OWN BODY. This helps eliminate the potential for your immune system to reject the cells and also eliminates the potential for disease transmission. Medications like NSAIDs and pain relievers can affect your vital organs. Invasive surgeries to replace joints with prosthetics can lead to a list of adverse outcomes; including death. Stem Cell Therapy is minimally invasive leaving a narrow margin for complications and adverse reactions.
If youve exhausted all traditional treatments or are not interested in surgery then you may want to consider stem cell therapy.
In the PAST the devices used to aspirate bone marrow were considered VERY painful, time-consuming, and extremely invasive. In 2017, this all changed when a new proprietary device for bone marrow aspiration received FDA clearance. This new device is THE ONLY bone marrow aspiration device makes the procedure virtually painless and is less invasive compared to other bone marrow aspiration methods.
Currently, Atlas Medical Center is one of the only offices in the DFW Metroplex that has been trained to use this revolutionary device for aspirating bone marrow.
Once your buttock areas has been thoroughly numbed and the cells are extracted they are immediately injected directly into the joint or area that is injured. Once injected, the healing process begins, and the stem cells begin sending signals to your immune system to get to work repairing the damage. This is all performed under ultrasound guidance so that there is ZERO guesswork (and the provider can see in REAL TIME exactly where the injection needs to be injected).
Our patients have reported that the procedure is virtually PAINLESS. The procedure requires NO general anesthesia (just local), is considered very safe, is the least invasive, requires no downtime, no hospitalization, and has shown to yield more cells (CFUs) compared to any other method. The proprietary method Atlas uses allows you to be in and out of our office in 45 minutes to 1 hour.
Patients are amazed that they can walk right out of our office and continue their usual daily activities without a single stitch- just a band aid (on their buttock and area that was treated). For example, the difference in recovery time between knee surgery versus a stem cell therapy procedure is astounding. So many patients have avoided sacrificing half a year of their life recovering from surgery by choosing stem cell therapy that has you returning to work usually on the same day!
The adipose technique that our medical providers utilize is also a virtually painless process, compared to other older techniques.
Using a local anesthetic, our medical team will take a small sample of fat tissue from your buttock. This process is usually painless, but some patients experience a slight, minimal discomfort. Once your fat cells have been collected and processed using a powerful centrifuge, they are injected under ultrasound guidance into the area of injury.
This minimally invasive procedure can be completed in 2-3 hours. The good news is there is no hospitalization, and it is an outpatient procedure. Theres a period where patients feel sore. This feeling usually lasts for a couple of days to a week. Patients are totally awake during the treatment, and most patients return to normal activities within 24-48 hours.
When Mesenchymal stem cells from either your fat or bone marrow are injected into an affected joint/s, they start to work to potentially repair and replace the damaged tissue. These cells incorporate themselves into the damaged area and over time begin to improve the stability of the tissue and reduce any pain being caused by the damage. Because mesenchymal stem cells work with your immune system to heal, they can also have an effect on inflammation. By reducing and regulating the chronic inflammation responsible for many joint conditions, mesenchymal stem cells deliver patients a rapid decrease in pain. Stem cells have been integral in advancing treatments for degeneration in the bones and joints, damaged cartilage in joints, labral and labrum tears, meniscus tears, osteoarthritis, tendinosis and a wide range of other ailments involving the joints.
On average, many patients start noticing improvement as soon as four to six weeks from the procedure, and some patients have experienced a noticeable reduction in pain as soon as a few days after treatment. There is no need for time off of work for a lengthy recovery period like with invasive surgery, and many patients return to work on the same day of their procedure. We encourage you to take it easy while your body embarks on its healing process, but normal to moderate activity is okay. As with any medical procedure, results vary and not everyone is going to be a candidate for stem cell therapy. Some patients may have to repeat the procedure again in a few months or a few years, so discussing treatment options for your specific needs is key. On your consultation day, all of your questions will be answered, and our medical provider will let you know if you qualify for this procedure.
Our purpose at Atlas Medical Center is to get you out of pain, improve mobility, and avoid having unnecessary surgeries. Our unique JointRenew Program is exclusive to the Atlas Medical Center. This advanced regenerative medical procedure uses a combination of two or more of the following: Stem Cell Therapy, Amniotic Cell Therapy, Cord Tissue Cell Therapy, Platelet Rich Plasma therapy, and Advanced Non-invasive laser therapy to optimize healing. Our clinical experience has shown that this combination accelerates healing; by allowing the greatest number of regenerative cells along with non-invasive technology to work together to potentially help regenerate the damaged area.
In addition, all of our medical providers are Board Certified, trained, and highly skilled in stem cell and regenerative cell procedures; and all injections are performed with ultrasound or fluoroscopy (real time x-ray). (This eliminates all guesswork so that the regenerative cells are injected precisely where they need to be.) This ensures that youre always receiving the best possible treatment and gives you the greatest chance for success!
Finally, our providers are currently one of the only ones in the Dallas-Fort Worth Metroplex using the ONLY FDA cleared device to aspirate bone marrow for stem cell therapy that doesnt require any manipulation.
Amniotic and Cord Cell Regenerative Therapy are alternative regenerative procedures for those who are not candidates for Stem Cell Therapy. Unlike bone marrow or adipose stem cell procedures, amniotic or Cord cell therapy is not health or condition dependent and offers those with arthritic joint conditions and soft tissue problems other treatment options.
For Dallas, Fort Worth or surrounding area patients, were located a short drive away in Irving and are looking forward to consulting with you.
See the rest here:
Stem Cell Therapy in Dallas, TX - atlasmedicalcenter.com
- In situ repair abilities of human umbilical cordderived mesenchymal stem cells and autocrosslinked hyaluronic acid gel complex in rhesus monkeys with... - May 23rd, 2020
- UH studying use of convalescent plasma to improve health of COVID-19 patients - Crain's Cleveland Business - May 23rd, 2020
- COVID-19: Recommendations for Treating MS and Related... : Neurology Today - LWW Journals - May 21st, 2020
- New hybrid embryos are the most thorough mixing of humans and mice yet - Science News - May 20th, 2020
- Hotel in Spain requires two negative Covid-19 tests to check in with a free antibody test during your stay - CNBC - May 20th, 2020
- 'Outpatient Is Still Chaos': What We Heard This Week - MedPage Today - May 20th, 2020
- Sumit Dewanjee, MD, is being recognized by Continental Who's Who - PRNewswire - May 7th, 2020
- Results From Pivotal Phase 2/3 Study of Emapalumab in Patients With Primary HLH Published in New England Journal of Medicine - BioSpace - May 7th, 2020
- COVID-19 Impact and Recovery Analysis | Global Cell Isolation Market 2020-2024 | Evolving Opportunities with Agilent Technologies Inc. and Becton,... - May 7th, 2020
- Stem Cell Alopecia Treatment Market Detailed Analysis of Current Industry Figures With Forecasts Growth by 2026 - 3rd Watch News - May 7th, 2020
- AMC to use stem cell therapy in treating graft-versus-host disease - Korea Biomedical Review - May 7th, 2020
- Drumming class finds a new rhythm with creative connections - Yes! Weekly - May 7th, 2020
- Drumming class finds a new rhythm with creative connections - Wake Forest University News Center - May 5th, 2020
- Insights on the Worldwide Cell Expansion Industry to 2027 - Analysis and Forecasts - Yahoo Finance UK - May 5th, 2020
- These 5 Houston-area research institutions have bright minds at work to battle COVID-19 - InnovationMap - May 5th, 2020
- GCC Condemns Israeli Plans to Annex Parts of the West Bank - Asharq Al-awsat English - May 2nd, 2020
- Jerusalem residents concerned Israel is changing their residency rights - Arabnews - May 2nd, 2020
- Four UTSW Researchers Named to The National Academy of Sciences - D Magazine - May 1st, 2020
- CHMP Grants Positive Opinion for DARZALEX (daratumumab) Subcutaneous Formulation for the Treatment of Patients with Multiple Myeloma - Yahoo Finance - May 1st, 2020
- Verify the URL - InnovationMap - May 1st, 2020
- Houston banking exec shares tips for keeping online information secure amid COVID-19 threats - InnovationMap - May 1st, 2020
- Trials and Tribulations: Neurology Research During COVID-19 - Medscape - April 30th, 2020
- Into the Lungs and Beyond - Harvard Medical School - April 30th, 2020
- Five UC San Diego Professors Elected to National Academy of Sciences - UC San Diego Health - April 29th, 2020
- Suffering from ED? Discover how our combined treatments of Hormone Balancing and FDA Approved Acoustic Wave Pulse Therapy Ends Your ED - Magazine of... - April 29th, 2020
- BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate UpdateThursday, May 7, 2020, 8:30 am EDT - BioSpace - April 29th, 2020
- What Is The Economic Value of Receiving CAR T-Cell Therapy in an Outpatient Setting? - AJMC.com Managed Markets Network - April 24th, 2020
- Healing the heart by returning it to its infancy - FierceBiotech - April 24th, 2020
- What Factors Influence Hematological Recovery in Patients Who Receive CAR-T Therapies? - Cancer Therapy Advisor - April 24th, 2020
- Academy adds new members from UW who 'expand the boundaries of knowledge' - University of Wisconsin-Madison - April 24th, 2020
- FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments - FDA.gov - April 24th, 2020
- A rampage through the body - Science Magazine - April 24th, 2020
- Israeli COVID-19 treatment with 100% survival rate tested on US patient - The Jerusalem Post - April 21st, 2020
- Stem Cell Therapy: A Promising Treatment for COVID-19? - Technology Networks - April 21st, 2020
- Meet the 5 female finalists for the 2020 M&T Bank John Travers Award - PennLive - April 21st, 2020
- Hackensack Meridian Health Studying the Blood of COVID-19 Survivors - The Ritz Herald - April 15th, 2020
- Reviewing the Latest Treatment Strategies in Patients with Transplant-Eligible Multiple Myeloma - Hematology Advisor - April 9th, 2020
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Trends and Forecast to 2026 | Takeda Pharmaceutical Company Limited, Cytori... - April 9th, 2020
- Canadian Company STEMCELL Technologies Is an Essential Industry Partner for COVID-19 Research and Vaccine Development - Business Wire - April 9th, 2020
- 3 drug candidates authorized to treat COVID-19 patients - Korea Biomedical Review - April 7th, 2020
- Surgeon offers innovative treatments - Brunswick News - April 7th, 2020
- Health Tech: Dallas-based American Heart Association Awards $14M in Research Grants for Heart, Brain, and COVID-19 Innovation - dallasinnovates.com - April 7th, 2020
- Metrion Biosciences and International Scientific Consortium Publish Data and New Recommendations for in Vitro Risk Assessment of the Cardiac Safety of... - April 7th, 2020
- YOUR HEALTH: Something fishy to help improve eyesight - WQAD.com - April 6th, 2020
- First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency... - April 6th, 2020
- Yiviva Announces Dosing of First Patient in Phase 2b Study of First-Line YIV-906 Plus Sorafenib Combination Therapy in the Treatment of Hepatocellular... - April 6th, 2020
- Coronavirus Business Tracker: How The Private Sector Is Fighting The COVID-19 Pandemic - Forbes - April 6th, 2020
- Treatment with CytoDyn's Leronlimab Indicates Significant Trend Toward Immunological Restoration in Severely Ill COVID-19 Patients - Associated Press - April 6th, 2020
- Coronavirus daily news update, April 6: What to know today about COVID-19 in the Seattle area, Washington state and the nation - Seattle Times - April 6th, 2020
- Celularity and Infectious Disease Research Institute will try out COVID-19 cell therapy - GeekWire - April 3rd, 2020
- Pinprick Blood Test To Identify Antibodies In Patients Approved By FDA - Kaiser Health News - April 3rd, 2020
- CytoDyn CEO Dr. Pourhassan to Appear on Fox Business Network Friday, April 3, 2020 at 2:00 pm ET to Discuss Leronlimab Treatment of 10 Severely Ill... - April 3rd, 2020
- Is There a New CAR T-Cell Treatment for Mantle Cell Lymphoma? - AJMC.com Managed Markets Network - April 3rd, 2020
- North Jersey hitting the surge - Politico - April 3rd, 2020
- PharmAbcine Announces Acceptance of Phase Ib Olinvacimab and Pembrolizuamb Combination Trial in rGBM Patients Abstract at the 2020 ASCO Annual Meeting... - April 3rd, 2020
- A word for those risking their lives amid the coronavirus crisis: Thanks - TwinCities.com-Pioneer Press - April 3rd, 2020
- AML Relapse: How IDH-Inhibitor Drugs Work To Achieve Remission Before Stem-Cell Transplant - SurvivorNet - April 2nd, 2020
- Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 Patients - Associated Press - March 31st, 2020
- 2020 Canada Gairdner Awards Recognize World-renowned Scientists for Transformative Contributions to Research That Impact Human Health - Benzinga - March 31st, 2020
- Sales Revenue of Scaffold Technology Market to Escalate in the Coming Years Owing to Rapid Growth in Consumer Adoption 2017 2025 - Lake Shore Gazette - March 31st, 2020
- San Diego Angel Conference Announces Investment of $400,000 in 3 Companies - Times of San Diego - March 31st, 2020
- About Stem Cell Center - March 28th, 2020
- From Bats to Human Lungs, the Evolution of a Coronavirus - The New Yorker - March 28th, 2020
- Leronlimab Used in Seven Patients with Severe COVID-19 Demonstrated Promise with Two Intubated Patients in ICU, Removed from ICU and Extubated with... - March 28th, 2020
- Live Updates: Coronavirus in the Bay Area: Phony Health 'Inspectors' Knocking on Doors -- Don't Let Them In - KQED - March 28th, 2020
- Veterans in Pain helps ease the pain for veterans - Tullahoma News and Guardian - March 25th, 2020
- Disruptions in Cancer Care in the Era of COVID-19 - Medscape - March 21st, 2020
- In vivo Comparison of the Biodistribution and Toxicity of InP/ZnS Quan | IJN - Dove Medical Press - March 21st, 2020
- A new therapeutic approach against COVID-19 Pneumonia - Institute for Ethics and Emerging Technologies - March 15th, 2020
- Toxicity minimal with novel transplantation approach for transfusion-dependent thalassemia - Healio - March 12th, 2020
- OncMadness: Meet the Blue Ribbon Panel - MedPage Today - March 12th, 2020
- Hatteras Island Cancer Foundation Celebrates 20 Years with Upcoming Annual Gala - Island Free Press - March 12th, 2020
- Scientists Grapple with US Restrictions on Fetal Tissue Research - The Scientist - March 2nd, 2020
- CAR T Cells to Go? Outpatient Therapy Can Be Safe - Medscape - February 28th, 2020
- TO YOUR HEALTH: Inflammation can drive triple-negative breast cancer - Dover Post - February 28th, 2020
- Impact of TP53 Mutation Clearance Prior to Allo-SCT - MedPage Today - February 28th, 2020
- Arctic Medical Center: Regenerative Medicine & Stem Cell ... - February 27th, 2020
- New study identifies trigger that turns dormant cancer stem cells into active ones - Benzinga - February 27th, 2020
- Bringing Transplant to More Patients With AML - MedPage Today - February 27th, 2020
- UCLA raises $5.49 billion in one of most ambitious campaigns ever by a public university - UCLA Newsroom - February 27th, 2020